Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes

• Status: Unknown status
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy of two dosages (600mg/day and 1200mg/day) of bicifadine SR with placebo for 14 weeks in reduction of chronic neuropathic patin (measured by a daily rating of pain intensity) associated with diabetic periperal neuropathy in adult outpatients.

To compare the tolerability of two dosages of bicifadine SR with placebo in adult outpaitens treated for chronic neuropathic pain for 14 weeks associated with diabetic peripheral neuropathy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: XTL Biopharmaceuticals

Criteria

Inclusion Criteria:

• Male or female, 18 years or older

• Diagnosis of type-1 or type 2 non-insulin dependent diabetes mellitus

• Chronic bilateral pain due to diabetic neuropathy

• Pain for at least six months

• Primary pain is located in the feet

• Others-contact site for information

Exclusion Criteria:

• Symptoms of other painful conditions

• Presence of amputations other than toes

• Clinically significant psychiatric or other neurological disorder

• Use of certain medications

• Clinically important other diseases

• Pregnancy

• History of alcohol or narcotic abuse within two years

• Others-contact site for information